Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
PetVivo Holdings's Sloan Ratio for the quarter that ended in Mar. 2026 was 0.00%.
Warning Sign:
When sloan ratio (-122.42)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.
As of Mar. 2026, PetVivo Holdings has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
PetVivo Holdings (OTCPK:PETV) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2026, PetVivo Holdings has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
PetVivo Holdings Sloan Ratio % Related Terms
PetVivo Holdings Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for PetVivo Holdings's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PETV vs FOFA, ARAY, GTHP: Sloan Ratio % Comparison
For the Medical Devices subindustry, PetVivo Holdings's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PetVivo Holdings Sloan Ratio % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PetVivo Holdings's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where PetVivo Holdings's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
PetVivo Holdings's Sloan Ratio for the fiscal year that ended in Mar. 2026 is calculated as
PetVivo Holdings's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was -2.311 (Jun. 2025 ) + -3.008 (Sep. 2025 ) + -2.191 (Dec. 2025 ) + -2.963 (Mar. 2026 ) = $-10.47 Mil.
PetVivo Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was -1.634 (Jun. 2025 ) + -2.194 (Sep. 2025 ) + -1.467 (Dec. 2025 ) + -0.812 (Mar. 2026 ) = $-6.11 Mil.
PetVivo Holdings's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 was 0 (Jun. 2025 ) + 0.007 (Sep. 2025 ) + 0.005 (Dec. 2025 ) + 0 (Mar. 2026 ) = $0.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PetVivo Holdings (PETV) has a Sloan Ratio % of 0.00% as of Mar. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on PetVivo Holdings and its competitors.
Is PetVivo Holdings' Sloan Ratio % too high?
PetVivo Holdings' current Sloan Ratio % is 0.00%. Overall, PetVivo Holdings has a GF Score™ of 40/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PetVivo Holdings' Sloan Ratio % compare to FOFA and ARAY?
PetVivo Holdings' Sloan Ratio % of 0.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Medical Devices & Instruments company?
A good Sloan Ratio % depends on the Medical Devices & Instruments industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on PetVivo Holdings and its competitors. PetVivo Holdings's current Sloan Ratio % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PetVivo Holdings stock overvalued right now?
Based on GuruFocus' analysis, PetVivo Holdings (PETV) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.50, compared to a current price of $0.63 — trading 26% above its estimated fair value. The current Sloan Ratio % is 0.00%. PetVivo Holdings' overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For PetVivo Holdings (PETV), the current Sloan Ratio % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PetVivo Holdings (PETV) Overvalued in 2026?
Based on GuruFocus' analysis, PetVivo Holdings stock appears to be overvalued.
The current stock price of $0.63 is trading 26% above its estimated GF Value™ of $0.50.
GuruFocus considers PetVivo Holdings to be Modestly Overvalued.
Key valuation signals for PETV:
Sloan Ratio %: 0.00%
GF Value™: $0.50 vs. price of $0.63 (26% above fair value)
No single metric tells the full story. See the PETV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PetVivo Holdings Inc is an emerging biomedical device company. It is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of several patents. The company has also begun the commercialization of its product Spryng with OsteoCushion technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses.
40GF Score
Get the complete analysis for PETV
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PETV has been successfully added to your 
